China Resources Pharmaceutical Group (3320) H1 2024 earnings summary

Executive summary

• Revenue for 1H2024 reached RMB128.6 billion, up 4.7% year-over-year, with net profit rising 10.2% to RMB5.54 billion; gross profit increased 5.9% to RMB20.93 billion and gross margin improved to 16.3%.

• Pharmaceutical manufacturing, distribution, and retail contributed 16.5%, 79.6%, and 3.9% of total revenue, respectively, with all segments delivering steady growth.

• The company declared its first interim dividend of RMB0.083 per share.

• Enhanced digitalization, green initiatives, and brand strength further consolidated industry leadership.

Financial highlights

• Net profit margin improved to 4.3% from 4.1% in 1H2023; operating cash flow improved by 72.9% year-over-year.

• Earnings per share was RMB0.41; net profit attributable to owners was RMB2.60 billion, down 2.9% year-over-year.

• Cash and cash equivalents stood at RMB22.3 billion as of June 30, 2024.

• Gearing ratio increased to 54.1% from 42.2% at year-end 2023; current ratio improved to 1.4:1.

• Net cash used in operating activities was RMB1.02 billion, a significant improvement from RMB3.77 billion used in 1H2023.

Outlook and guidance

• Focus on high-quality growth through digital transformation, green initiatives, and integrated business layout, including TCM modernization and innovation in chemical and biological drugs.

• Continued pursuit of external M&A and internal restructuring to enhance synergy and expand product portfolio.

• Ongoing investment in R&D, with over 350 projects in the pipeline and increased collaboration with domestic and international partners.